Mr. Tupin was previously Audit Director of Sygnatures, the largest private audit and consulting company in Toulouse, France. He spent more than seven years at PriceWaterhouseCoopers with 2 years of international experience in Canada. He has worked on a number of high-profile business transactions, including the Alcan Group takeover bid for Pechiney and the consolidation audit of Pechiney for Alcan. Mr. Tupin has been a French C.P.A. since 2002.
Chief Medical Officer and Head of R&D
Dr. Scott brings extensive clinical development and regulatory experience, having held senior leadership positions in global pharma and emerging biotech for over thirty years. Most recently, Dr. Scott retired as Chief Medical Oﬃcer at AbbVie, where he had responsibility for around 40 new molecular entities, four thousand people and a budget of around three billion dollars. During his tenure, Abbvie achieved over 14 major regulatory approvals including Venclexta, Orilissa, Skyrizi and Rinvoq. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics and big data to design and implement better clinical trials. In his previous roles at J&J, Pfizer and Amgen, Dr. Scott oversaw the development of blockbusters such as Lipitor, Norvasc, Caduet and Repatha. Dr. Scott pioneered the conduct of large scale cardiovascular trials performed by emerging pharma during his time at Atherogenics with the ARISE Trial. Dr. Scott was a member of the FDA Cardiac and Renal Drug Advisory Committee and also served on the Endocrine & Metabolic Committee from 2012 to 2016.
Sr. Vice President, Clinical Development
Senior Advisor in ophthalmology
Jérôme has over 30 years' experience in the management of pharmaceutical and biotech companies in France and abroad. Before joining ABIONYX Pharma, Jérôme Martinez was COO in France for the Japanese pharmaceutical company SANTEN, specializing in ophthalmology and rheumatology. From 2004 to 2011, he was Chairman of the Board of Novagali Pharma, a laboratory specializing in ophthalmology, where he oversaw Novagali Pharma's IPO and its sale to SANTEN in 2012. With a background in pharmacology, Jérôme Martinez holds a Master of Law in Health Administration from the Paris XI University, and an MBA from HEC Paris / Keio University in Japan. He is also a graduate of the JL Kellogg Graduate School of Management at Northwestern University in Chicago and is certified in the International Director Program at INSEAD.